Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)
      QxMD      Google Scholar   
Citation:
Blood Adv vol 5 (13) 2775-87
Year:
2021
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Book Volume:
10
Parents:
607  
Children:
None
Program:
OGC
Primary Committee:
Leukemia
Sec. Committees:
   
Pharmas:
Deltec Inc  
Grants:
U10CA180821, U10CA180882, UG1CA233338, U24CA196171, P30CA033572, UG1CA233180, UG1CA233191, UG1CA233327, UG1CA233331, UG1CA233339, UG1CA189848, UG1CA189850, UG1CA189858  
Corr. Author:
 
Authors:
                                         
Networks:
CA043, IA018, LAPS-AL002, LAPS-IL057, LAPS-MA036, LAPS-MO011, LAPS-NY158, LAPS-OH007, MUSC, NORTHWELL, OH070, SCOR   
Study
CALGB-10201
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: